Vivos Therapeutics, Inc. (VVOS) Analyst Estimates Annual - Discounting Cash Flows
VVOS
Vivos Therapeutics, Inc.
VVOS (NASDAQ)
Period Ending: 2027
12-31
2026
12-31
2025
12-31
2024
12-31
2023
12-31
2022
12-30
2021
12-30
2020
12-30
Number of Analysts 1 3 2 1 1 1 1 1
Estimated Revenue
Low 46.83 28.87 19.28 13.65 12.59 16 14.82 11.08
Average 52.15 29.01 19.37 15.2 14.02 16.55 17.3 12.94
High 54.43 29.15 19.45 15.87 14.63 17.1 19.41 14.51
Estimated EBITDA
Low -49.67 -26.6 -17.75 -14.48 -13.35 -15.6 -17.71 -13.24
Average -47.59 -26.47 -17.67 -13.87 -12.79 -15.1 -15.79 -11.81
High -42.73 -26.35 -17.6 -12.46 -11.49 -14.6 -13.52 -10.11
Estimated EBIT
Low -50.69 -27.15 -18.11 -14.78 -13.63 -15.92 -18.07 -13.52
Average -48.56 -27.02 -18.03 -14.16 -13.06 -15.41 -16.11 -12.05
High -43.61 -26.89 -17.96 -12.71 -11.72 -14.9 -13.8 -10.32
Estimated Net Income
Low 0 -6.63 -10.43 -10.72 -31.34 -154.1 -130.8 -87.22
Average 0 -6.04 -9.5 -9.76 -28.53 -131.1 -112.9 -75.3
High 0 -5.44 -8.56 -8.79 -25.72 -108.2 -91.86 -61.24
Estimated SGA Expenses
Low 79.75 49.17 32.84 23.25 21.44 27.25 25.23 18.87
Average 88.81 49.41 32.98 25.89 23.88 28.18 29.46 22.03
High 92.69 49.65 33.12 27.02 24.92 29.12 33.05 24.72
Estimated EPS
Low 0 -1.32 -2.08 -2.13 -6.24 -30.7 -26.06 -17.38
Average 0 -1.25 -1.97 -2.02 -5.91 -26.5 -22.5 -15
High 0 -1.08 -1.71 -1.75 -5.12 -21.55 -18.3 -12.2
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program